莎普爱思获得去氧肾上腺素酮咯酸溶液临床试验批准通知书

Core Viewpoint - The company, Shapais (603168.SH), has received approval from the National Medical Products Administration for clinical trials of a new drug, deoxymidodrine ketorolac solution, aimed at maintaining pupil dilation during cataract surgery and alleviating postoperative eye pain [1] Group 1 - The drug is specifically indicated for use during cataract surgery or artificial lens replacement procedures [1] - The company plans to initiate clinical trials once conditions are met [1] - Cumulative research and development investment in the deoxymidodrine ketorolac solution project has reached approximately 5.5563 million RMB [1]